Lantern Pharma Inc.
NASDAQ:LTRN

Watchlist Manager
Lantern Pharma Inc. Logo
Lantern Pharma Inc.
NASDAQ:LTRN
Watchlist
Price: 3.08 USD 4.41% Market Closed
Market Cap: 33.2m USD
Have any thoughts about
Lantern Pharma Inc.?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-0.2
Current
-0.3
Median
4.2
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-0.2
=
Enterprise Value
5.2m USD
/
EBITDA
-21.2m USD
All Countries
Close
Market Cap EV/EBITDA
US
Lantern Pharma Inc.
NASDAQ:LTRN
33.2m USD -0.2
FR
Pharnext SCA
OTC:PNEXF
6T USD -219 796.6
US
Abbvie Inc
NYSE:ABBV
312.7B USD 15.3
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 17.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD 24.1
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 9.9
US
Epizyme Inc
F:EPE
94.1B EUR -514.1
AU
CSL Ltd
ASX:CSL
133.6B AUD 20.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.3B USD 15.9
US
Seagen Inc
F:SGT
39.3B EUR -58.7
NL
argenx SE
XBRU:ARGX
34.8B EUR -105.5
EBITDA Growth
US
Lantern Pharma Inc.
NASDAQ:LTRN
Average EV/EBITDA: 17.2
Negative Multiple: -0.2
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.9
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -105.5 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-0.2
2-Years Forward
EV/EBITDA
-0.1
3-Years Forward
EV/EBITDA
N/A

See Also

Discover More